Experimental Hematology
Volume 36, Issue 11 , Pages 1461-1470 , November 2008

Targeting of heat-shock protein 32/heme oxygenase-1 in canine mastocytoma cells is associated with reduced growth and induction of apoptosis

  • Emir Hadzijusufovic

      Affiliations

    • Department of Companion Animals and Horses, Clinic for Internal Medicine and Infectious Diseases, University of Veterinary Medicine Vienna, Austria
    • Department of Internal Medicine I, Division of Hematology and Hemostaseology
    • ,
  • Laura Rebuzzi

      Affiliations

    • Department of Companion Animals and Horses, Clinic for Internal Medicine and Infectious Diseases, University of Veterinary Medicine Vienna, Austria
    • Department of Internal Medicine I, Division of Hematology and Hemostaseology
    • ,
  • Karoline V. Gleixner

      Affiliations

    • Department of Internal Medicine I, Division of Hematology and Hemostaseology
    • ,
  • Veronika Ferenc

      Affiliations

    • Department of Internal Medicine I, Division of Hematology and Hemostaseology
    • ,
  • Barbara Peter

      Affiliations

    • Department of Companion Animals and Horses, Clinic for Internal Medicine and Infectious Diseases, University of Veterinary Medicine Vienna, Austria
    • Department of Internal Medicine I, Division of Hematology and Hemostaseology
    • ,
  • Rudin Kondo

      Affiliations

    • Department of Internal Medicine I, Division of Hematology and Hemostaseology
    • ,
  • Alexander Gruze

      Affiliations

    • Institute of Immunology
    • ,
  • Michael Kneidinger

      Affiliations

    • Department of Internal Medicine I, Division of Hematology and Hemostaseology
    • ,
  • Maria-Theresa Krauth

      Affiliations

    • Department of Internal Medicine I, Division of Hematology and Hemostaseology
    • ,
  • Matthias Mayerhofer

      Affiliations

    • Clinical Institute of Medical and Chemical Laboratory Diagnostics
    • ,
  • Puchit Samorapoompichit

      Affiliations

    • Center of Anatomy and Cell Biology, Medical University of Vienna, Austria
    • ,
  • Khaled Greish

      Affiliations

    • Laboratory of Microbiology and Oncology, Faculty of Pharmaceutical Sciences, Sojo University, Kumamoto and BioDynamics Research Laboratory, Kumamoto, Japan
    • ,
  • Arun K. Iyer

      Affiliations

    • Laboratory of Microbiology and Oncology, Faculty of Pharmaceutical Sciences, Sojo University, Kumamoto and BioDynamics Research Laboratory, Kumamoto, Japan
    • ,
  • Winfried F. Pickl

      Affiliations

    • Institute of Immunology
    • ,
  • Hiroshi Maeda

      Affiliations

    • Laboratory of Microbiology and Oncology, Faculty of Pharmaceutical Sciences, Sojo University, Kumamoto and BioDynamics Research Laboratory, Kumamoto, Japan
    • ,
  • Michael Willmann

      Affiliations

    • Department of Companion Animals and Horses, Clinic for Internal Medicine and Infectious Diseases, University of Veterinary Medicine Vienna, Austria
    • ,
  • Peter Valent

      Affiliations

    • Department of Internal Medicine I, Division of Hematology and Hemostaseology
    • Corresponding Author InformationOffprint requests to: Peter Valent, M.D., Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, AKH-Wien, Waehringer Guertel 18-20, A-1090 Vienna, Austria

Received 13 December 2007 ,Revised 2 June 2008 ,Accepted 3 June 2008.

References 

  1. Lennert K, Parwaresch MR. Mast cells and mast cell neoplasia: a review. Histopathology. 1979;3:349–365
  2. Metcalfe DD. Classification and diagnosis of mastocytosis: current status. J Invest Dermatol. 1991;96:2S–4S
  3. Valent P. Biology, classification and treatment of human mastocytosis. Wien Klin Wochenschr. 1996;108:385–397
  4. Valent P, Akin C, Sperr WR, et al. Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol. 2003;122:695–717
  5. Akin C, Metcalfe DD. Systemic mastocytosis. Annu Rev Med. 2004;55:419–432
  6. Valent P, Horny H-P, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Conference Report of “Year 2000 Working Conference on Mastocytosis.”. Leuk Res. 2001;25:603–625
  7. Valent P, Akin C, Escribano L, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest. 2007;37:435–453
  8. Wilson TM, Metcalfe DD, Robyn J. Treatment of systemic mastocytosis. In: Immunol Allergy Clin North Am. 2006;26:549–573.
  9. Valent P, Ghannadan M, Akin C, et al. On the way to targeted therapy of mast cell neoplasms: identification of molecular targets in neoplastic mast cells and evaluation of arising treatment concepts. Eur J Clin Invest. 2004;34:41–52
  10. Macy DW. Canine mast cell tumors. Vet Clin North Am Small Anim Pract. 1985;15:783–803
  11. London CA, Seguin B. Mast cell tumors in the dog. Vet Clin North Am Small Anim Pract. 2003;33:473–489
  12. Misdorp W. Mast cells and canine mast cell tumours. A review. Vet Q. 2004;26:156–169
  13. Rogers KS. Mast cell tumors: dilemmas of diagnosis and treatment. Vet Clin North Am Small Anim Pract. 1996;26:87–102
  14. Govier SM. Principles of treatment for mast cell tumors. Clin Tech Small Anim Pract. 2003;18:103–106
  15. Cahalane AK, Payne S, Barber LG, et al. Prognostic factors for survival of dogs with inguinal and perineal mast cell tumors treated surgically with or without adjunctive treatment: 68 cases (1994–2002). J Am Vet Med Assoc. 2004;225:401–408
  16. Nagata H, Worobec AS, Oh CK, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A. 1995;92:10560–10564
  17. Longley BJ, Tyrrell L, Lu SZ, et al. Somatic c-kit activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet. 1996;12:312–314
  18. Fritsche-Polanz R, Jordan JH, Feix A, et al. Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. Br J Haematol. 2001;113:357–364
  19. London CA, Galli SJ, Yuuki T, et al. Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit. Exp Hematol. 1999;27:689–697
  20. Zemke D, Yamini B, Yuzbasiyan-Gurkan V. Mutations in the juxtamembrane domain of c-KIT are associated with higher grade mast cell tumors in dogs. Vet Pathol. 2002;39:529–535
  21. Jones CL, Grahn RA, Chien MB, et al. Detection of c-kit mutations in canine mast cell tumors using fluorescent polyacrylamide gel electrophoresis. J Vet Diagn Invest. 2004;16:95–100
  22. Riva F, Brizzola S, Stefanello D, et al. A study of mutations in the c-kit gene of 32 dogs with mastocytoma. J Vet Diagn Invest. 2005;17:385–388
  23. Webster JD, Yuzbasiyan-Gurkan V, Miller RA, Kaneene JB, Kiupel M. Cellular proliferation in canine cutaneous mast cell tumors: associations with c-KIT and its role in prognostication. Vet Pathol. 2007;44:298–308
  24. Webster JD, Kiupel M, Yuzbasiyan-Gurkan V. Evaluation of the kinase domain of c-KIT in canine cutaneous mast cell tumors. BMC Cancer. 2006;6:85
  25. Taylor ML, Metcalfe DD. Kit signal transduction. Hematol Oncol Clin North Am. 2000;14:517–535
  26. Casteran N, De Sepulveda P, Beslu N, et al. Signal transduction by several KIT juxtamembrane domain mutations. Oncogene. 2003;22:4710–4722
  27. Shivakrupa R, Bernstein A, Watring N, Linnekin D. Phosphatidylinositol 3'-kinase is required for growth of mast cells expressing the kit catalytic domain mutant. Cancer Res. 2003;63:4412–4419
  28. Dennery PA. Regulation and role of heme oxygenase in oxidative injury. Curr Top Cell Regul. 2000;36:181–199
  29. Morse D, Choi AM. Heme oxygenase-1: the “emerging molecule” has arrived. Am J Respir Cell Mol Biol. 2002;27:8–16
  30. Takahashi T, Morita K, Akagi R, Sassa S. Heme oxygenase-1: a novel therapeutic target in oxidative tissue injuries. Curr Med Chem. 2004;11:1545–1561
  31. Doi K, Akaike T, Fujii S, et al. Induction of haem oxygenase-1 nitric oxide and ischaemia in experimental solid tumours and implications for tumour growth. Br J Cancer. 1999;80:1945–1954
  32. Fang J, Sawa T, Akaike T, et al. In vivo antitumor activity of pegylated zinc protoporphyrin: targeted inhibition of heme oxygenase in solid tumor. Cancer Res. 2003;63:3567–3574
  33. Fang J, Sawa T, Akaike T, Greish K, Maeda H. Enhancement of chemotherapeutic response of tumor cells by a heme oxygenase inhibitor, pegylated zinc protoporphyrin. Int J Cancer. 2004;109:1–8
  34. Mayerhofer M, Gleixner KV, Mayerhofer J, et al. Targeting of heat shock protein 32 (Hsp32) / heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinib. Blood. 2008;111:2200–2210
  35. Liu ZM, Chen GG, Ng EK, Leung WK, Sung JJ, Chung SC. Upregulation of heme oxygenase-1 and p21 confers resistance to apoptosis in human gastric cancer cells. Oncogene. 2004;23:503–513
  36. Berberat PO, Dambrauskas Z, Gulbinas A, et al. Inhibition of heme oxygenase-1 increases responsiveness of pancreatic cancer cells to anticancer treatment. Clin Cancer Res. 2005;11:3790–3798
  37. Zhou P, Kalakonda N, Comenzo RL. Changes in gene expression profiles of multiple myeloma cells induced by arsenic trioxide (ATO): possible mechanisms to explain ATO resistance in vivo. Br J Haematol. 2005;128:636–644
  38. Takamiya R, Murakami M, Kajimura M, et al. Stabilization of mast cells by heme oxygenase-1: an anti-inflammatory role. Am J Physiol Heart Circ Physiol. 2002;283:861–870
  39. Kondo R, Gleixner KV, Mayerhofer M, et al. Identification of heat shock protein 32 (Hsp32) as a novel survival factor and therapeutic target in neoplastic mast cells. Blood. 2007;110:661–669
  40. Fabbro D, Ruetz S, Bodis S, et al. PKC412—a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des. 2000;15:17–28
  41. Iyer AK, Greish K, Fang J, Murakami R, Maeda H. High-loading nanosized micelles of copoly(styrene-maleic acid)-zinc protoporphyrin for targeted delivery of a potent heme oxygenase inhibitor. Biomaterials. 2007;28:1871–1881
  42. Greish K, Nagamitsu A, Fang J, Maeda H. Copoly(styrene-maleic acid)-pirarubicin micelles: high tumor-targeting efficiency with little toxicity. Bioconjug Chem. 2005;16:230–236
  43. DeVinney R, Gold WM. Establishment of two dog mastocytoma cell lines in continuous culture. Am J Respir Cell Mol Biol. 1990;3:413–420
  44. Rebuzzi L, Willmann M, Sonneck K, et al. Detection of vascular endothelial growth factor (VEGF) and VEGF receptors Flt-1 and KDR in canine mastocytoma cells. Vet Immunol Immunopathol. 2007;115:320–333
  45. Valent P, Ashman LK, Hinterberger W, et al. Mast cell typing: demonstration of a distinct hematopoietic cell type and evidence for immunophenotypic relationship to mononuclear phagocytes. Blood. 1989;73:1778–1785
  46. Gleixner K, Mayerhofer M, Aichberger K, et al. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA), and evaluation of cooperative drug effects. Blood. 2005;107:752–759
  47. Agis H, Krauth MT, Mosberger I, et al. Enumeration and immunohistochemical characterisation of bone marrow basophils in myeloproliferative disorders using the basophil specific monoclonal antibody 2D7. J Clin Pathol. 2006;59:396–402
  48. Gleixner KV, Rebuzzi L, Mayerhofer M, et al. Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells. Exp Hematol. 2007;35:1510–1521

PII: S0301-472X(08)00266-X

doi: 10.1016/j.exphem.2008.06.002

Experimental Hematology
Volume 36, Issue 11 , Pages 1461-1470 , November 2008

Article Tools

* Image Usage & Resolution